| Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase … D Marin, AR Ibrahim, C Lucas, G Gerrard, L Wang, RM Szydlo, RE Clark, ... Journal of Clinical Oncology 30 (3), 232, 2012 | 586 | 2012 |
| UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia AK Fielding, JM Rowe, G Buck, L Foroni, G Gerrard, MR Litzow, ... Blood, The Journal of the American Society of Hematology 123 (6), 843-850, 2014 | 403 | 2014 |
| Regulation of myeloid leukaemia by the cell-fate determinant Musashi T Ito, HY Kwon, B Zimdahl, KL Congdon, J Blum, WE Lento, C Zhao, ... Nature 466 (7307), 765-768, 2010 | 398 | 2010 |
| Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy AR Ibrahim, L Eliasson, JF Apperley, D Milojkovic, M Bua, R Szydlo, ... Blood 117 (14), 3733, 2011 | 391 | 2011 |
| Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL … B Patel, L Rai, G Buck, SM Richards, Y Mortuza, W Mitchell, G Gerrard, ... British journal of haematology 148 (1), 80-89, 2010 | 178 | 2010 |
| Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations AJ Bench, HE White, L Foroni, AL Godfrey, G Gerrard, S Akiki, A Awan, ... British journal of haematology 160 (1), 25-34, 2013 | 134 | 2013 |
| Guidelines for the measurement of BCR‐ABL1 transcripts in chronic myeloid leukaemia L Foroni, G Wilson, G Gerrard, J Mason, D Grimwade, HE White, ... British journal of haematology 153 (2), 179-190, 2011 | 123 | 2011 |
| Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine G Gerrard, E Payne, RJ Baker, DT Jones, M Potter, HG Prentice, M Ethell, ... Haematologica 89 (7), 782-790, 2004 | 121 | 2004 |
| Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies P Neelakantan, G Gerrard, C Lucas, D Milojkovic, P May, L Wang, ... Blood, The Journal of the American Society of Hematology 121 (14), 2739-2742, 2013 | 111 | 2013 |
| A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR H White, L Deprez, P Corbisier, V Hall, F Lin, S Mazoua, S Trapmann, ... Leukemia 29 (2), 369-376, 2015 | 96 | 2015 |
| Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients D Milojkovic, JF Apperley, G Gerrard, AR Ibrahim, R Szydlo, M Bua, ... Blood, The Journal of the American Society of Hematology 119 (8), 1838-1843, 2012 | 81 | 2012 |
| Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis CJ Harrison, H Mazzullo, FM Ross, KL Cheung, G Gerrard, L Harewood, ... British journal of haematology 117 (2), 427-435, 2002 | 81 | 2002 |
| BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation M Alikian, G Gerrard, PG Subramanian, K Mudge, P Foskett, ... American journal of hematology 87 (3), 298-304, 2012 | 74 | 2012 |
| Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) by real-time quantitative … H Pfeifer, G Cazzaniga, VHJ Van der Velden, JM Cayuela, B Schäfer, ... Leukemia 33 (8), 1910-1922, 2019 | 68 | 2019 |
| Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results CJ Harrison, H Mazzullo, KL Cheung, G Gerrard, GR Jalali, A Mehta, ... British journal of haematology 120 (6), 944-952, 2003 | 65 | 2003 |
| hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia A Bazeos, D Marin, AG Reid, G Gerrard, D Milojkovic, PC May, ... Leukemia 24 (6), 1243-1245, 2010 | 64 | 2010 |
| Target enrichment and high‐throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond‐Blackfan anaemia G Gerrard, M Valgañón, HE Foong, D Kasperaviciute, D Iskander, L Game, ... British journal of haematology 162 (4), 530-536, 2013 | 59 | 2013 |
| Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale NCP Cross, HE White, T Ernst, L Welden, C Dietz, G Saglio, FX Mahon, ... Leukemia 30 (9), 1844-1852, 2016 | 58 | 2016 |
| Technical aspects and clinical applications of measuring BCR‐ABL1 transcripts number in chronic myeloid leukemia L Foroni, G Gerrard, E Nna, JS Khorashad, D Stevens, B Swale, ... American journal of hematology 84 (8), 517-522, 2009 | 51 | 2009 |
| Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors G Nteliopoulos, A Bazeos, S Claudiani, G Gerrard, E Curry, R Szydlo, ... Haematologica 104 (12), 2400, 2019 | 49 | 2019 |
apperley jProfessor of Hemato-oncology, Imperial CollegeVerified email at imperial.ac.uk
